Oncosil Medical Ltd has released a press release.
Appendix 4C - Quarterly Cash Flow
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- Pancreatic cancer clinical study update
- Receipt of $2.3m R & D Tax Incentive Refund
- Appendix 4E - Preliminary final report 30 June 2016
- Hot Calibration Run of the OncoSil Device
- FDA IDE Approval
Later from OncoSil Medical
- Ethics Approval for OncoPac Clinical Study
- MHRA Approval to commence study in UK
- Appendix 4D & Half Year Accounts
- First subject recruited
- UK Central Ethics Approval
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical